← Back to Home

Oral Wegovy Goes on Sale in the UK as the Weight-Loss Drug Market Moves From Syringes to Pharmacy Shelves

Once-daily semaglutide lets GLP-1 treatment cross the injection barrier, while also bringing medical review, online pharmacy safety, and gaps in public coverage into sharper focus.

By SURL BioNews

Obesity treatment is going through a shift that may look routine but carries deep market significance: the same GLP-1 drug is moving from a product that requires refrigeration and injection to a tablet that patients can swallow every day. After Novo Nordisk’s oral semaglutide Wegovy received MHRA approval in the UK, private sales have begun through high-street and online pharmacies. This is not only the launch of a new dosage form; it is also a test of how the UK healthcare system will respond to rapidly expanding demand for weight-loss drugs.

According to UK media reports, this oral Wegovy has not yet entered routine NHS supply because it is still awaiting completion of NICE’s assessment. As a result, at this stage it is mainly being obtained privately by eligible people. The approval conditions cover adults with a BMI of 30 or above, or those with a BMI between 27 and 30 and at least one weight-related health problem. That means the drug formally remains a prescription treatment, rather than a general wellness product.

Demand in the early launch period has been very strong. The Times said that tens of thousands of patients in the UK have sought this once-daily Wegovy tablet, and channels including Boots, Asda, Superdrug, and Simple Online Pharmacy have seen unusually high levels of inquiries or sales. This enthusiasm is not hard to understand: for people who are afraid of injections, find it inconvenient to store injection pens, or want a treatment process closer to ordinary daily medication, the oral dosage form lowers both psychological and operational barriers.

But convenience does not mean simplicity. When Superdrug Online Doctor previously announced that it was starting sales, reports said the starting price for new patients for a one-month supply of the 1.5 mg dose was GBP79, and that users first had to complete an online clinical assessment, including information such as weight, height, and medical history, before a healthcare professional would decide whether to issue a prescription. Reports also said that 1.5 mg and 4 mg doses were initially available, with 9 mg and 25 mg strengths expected to be added later. These details show that oral Wegovy still needs to be adjusted step by step through a medical process, rather than serving as an instant weight-loss shortcut.

Clinical data provided the main basis for this launch. Reports at the time of the UK approval in June said trial participants lost about 14% to 17% of their body weight after 64 weeks. However, figures of this kind come from controlled research settings and may not fully predict long-term use in the real world, weight regain after stopping treatment, adherence, and management of side effects. Oral semaglutide also has more specific requirements for how it is taken, and if everyday use does not meet those requirements, its effect may be reduced.

The larger risk lies in the supply chain and the boundaries of regulation. The global popularity of GLP-1 drugs in recent years has already raised concerns about counterfeit medicines, unauthorized online sales, and inappropriate prescribing. If oral tablets are easier to mail and resell, these problems may become harder to detect. For regulators and pharmacies, the next step is not only making sure patients can buy the drug, but also confirming who is suitable to use it, who is monitoring side effects, and whether patients are receiving genuinely compliant medicines.

After the United States and the United Arab Emirates, the UK has become one of the earlier markets to approve oral Wegovy tablets, making it a window into the commercialization of obesity medicine. If NICE gives a positive recommendation in the future, NHS coverage could change access. If the assessment is more conservative, the gap between the private-pay market and public healthcare will continue to widen. For patients, the tablet does make treatment closer to everyday life, but it remains a medical option that requires a prescription, monitoring, and long-term judgment.

References

  1. The Guardian
  2. The Times
  3. The Scottish Sun
  4. The Guardian